Blood Tests to Help Diagnose and Track Endometriosis
Studies blood markers to help diagnose endometriosis in women aged 18 to 45.
Plain-language title generated from the registry record
Registry title: Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. (ENDOBIO)
Key facts
- Where
- Stockholm and Uppsala, SwedenSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT05339451, who can take part
Where in Sweden
- Karolinska Universitetssjukhus HuddingeStockholm, SwedenTaking people
- Södersjukhuset KvinnoklinikenStockholm, SwedenTaking people
- Akademiska UppsalaUppsala, SwedenNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Region Stockholm
- Trial code
- NCT05339451
- Record updated
- 24 February 2025
- Original description
Endometriosis is a chronic, benign, estrogen-dependent disease characterized by endometrial tissue that is implanted outside the uterus into the ovaries, intestines, or peritoneum but also outside the pelvis. It is a common disease that affects 7-10% of women around the world. The most common symptoms are pain and infertility. The diagnosis is histological after removal of lesions with laparoscopy (sensitivity 94%, specificity 79%), and treatment is symptomatic.Read full original descriptionShow less
Blood and Tissue Markers for Improving Diagnosis and Prognosis of Endometriosis. a Prospective Multicenter Nationwide Study. (ENDOBIO)
Endometriosis is a chronic, benign, estrogen-dependent disease characterized by endometrial tissue that is implanted outside the uterus into the ovaries, intestines, or peritoneum but also outside the pelvis. It is a common disease that affects 7-10% of women around the world. The most common symptoms are pain and infertility. The diagnosis is histological after removal of lesions with laparoscopy (sensitivity 94%, specificity 79%), and treatment is symptomatic.
At present, there is not a laboratory test that allows early and adequate diagnosis of endometriosis and therefore it can take up to 10 years for a patient to be diagnosed and patients often suffer from the disease.
The purpose of our study is to investigate biomarkers associated with endometriosis and prove their use in the diagnosis and staging of endometriosis. The biomarkers will be studied even in relationship to clinical manifestations of the disease, as markers of relapse and as fertility markers. Meanwhile, quality of life of patients with advanced stages of endometriosis postoperatively will be studied.
Exclusion: corticosteroids in the last 3 months; premature ovarian failure; pelvic inflammatory disease (PID); current or previous malignancy; pituitary, kidney, liver, adrenal disease; cardiovascular or systemic inflammatory diseases; BMI> 40; postmenopausal women; pregnancy and 6 months postpartum; endometrial hyperplasia or endometrial polyp.
IInclusion Criteria:; women of reproductive age (18-45) who are operated because of suspected endometriosis (dysmenorrhea, dyspareunia, infertility, etc.) (patient group); women of reproductive age (18-45) who are operated for other benign gynecological causes with laparoscopy (ovarian cysts, sterilization, fibroids, etc.) and are found without macroscopic endometriosis perioperatively and confirmed with blind biopsies (control group; talk swedish or english in order to complete questionnaires and give informed consent for their participation in the study.